Unknown PHASE2 INTERVENTIONAL NCT00740467

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation

Sponsor: Institut Paoli-Calmettes

Conditions Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Precancerous Condition

Interventions anti-thymocyte globulin busulfan cyclophosphamide cyclosporine fludarabine phosphate mycophenolate mofetil nonmyeloablative allogeneic hematopoietic stem cell transplantation

Updated 5 times since 2017 Last updated: Jan 27, 2010 Started: Jan 31, 2008 Primary completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Graft Versus Host Disease and Leukemia, this trial is ongoing. The trial is conducted by Institut Paoli-Calmettes and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Paoli-Calmettes

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Marseille, France